Caplin Point

Caplin Point Laboratories has received approval from the United States Food and Drug Administration (USFDA) for its Milrinone injection, a cardiovascular drug used in the management of heart failure and related conditions. The approval allows the Indian pharmaceutical firm to market the therapy in the U.S., a key market for high-value generic injectables. This milestone strengthens Caplin Point’s presence in the cardiovascular segment while showcasing its ability to meet stringent regulatory standards.

Caplin Point Laboratories has secured approval from the U.S. Food and Drug Administration (USFDA) for its Milrinone Lactate Injection, a critical drug used in treating patients with severe heart failure. The regulatory clearance represents a significant step for the Chennai-based pharmaceutical company as it seeks to expand its footprint in the U.S. generics market.